METASTATIC TRIPLE-NEGATIVE BREAST CANCER
Clinical trials for METASTATIC TRIPLE-NEGATIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC TRIPLE-NEGATIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for METASTATIC TRIPLE-NEGATIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo targets hard-to-treat breast cancer in patients with metabolic problems
Disease control Recruiting nowThis study tests whether adding the experimental drug evexomostat (SDX-7320) to standard chemotherapy (eribulin) works better than chemotherapy alone for people with metastatic triple-negative breast cancer who also have metabolic dysfunction (like insulin resistance). About 55 p…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 26, 2026 08:02 UTC
-
New drug combo aims to control aggressive breast cancer
Disease control Recruiting nowThis study tests whether combining two drugs, naxitamab and sacituzumab govitecan, is safe and effective for people with triple-negative breast cancer that has spread to other parts of the body. About 31 adults with this type of cancer will receive the combination therapy. The go…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 07:56 UTC
-
New hope for tough breast cancer: drug combo trial launches
Disease control Recruiting nowThis study tests two combinations of cancer drugs for people with metastatic triple-negative breast cancer that has not responded to one prior treatment. The drugs target cancer cells and boost the immune system to fight the disease. The goal is to see if these combinations are s…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Yale University • Aim: Disease control
Last updated May 22, 2026 14:01 UTC